<?xml version="1.0" encoding="UTF-8"?>
<p id="p0250">Further advantages of the drugs are the minimal adverse effects (headache, tiredness and nausea) and oral administration. The outcomes encourage clinical trials to verify the combined activity of SBV and antiviral drugs to treat COVID-19.
 <xref rid="b0585" ref-type="bibr">
  <sup>117</sup>
 </xref> Reports of ongoing clinical trials in the Iranian Registry of Clinical Trials (IRCT) regard the efficacy and safety of SBV (46784) monotherapy or plus Velpatasvir (46790), Daclatasvir (46463), Ledipasvir (46567) in patients diagnosed with SARS-CoV-2 showing mild, moderate and extreme symptoms.
 <xref rid="b0590" ref-type="bibr">
  <sup>118</sup>
 </xref> The data can indicate and, possibly, redirect the repurposing of drugs against COVID-19.
</p>
